The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial

Exclusion Criteria

• •Diagnosis of Alzheimer's disease (AD) or other form of dementia or significant neurological disorder
• •Parent or sibling who developed premature dementia \<60y (suggestive of a familial monogenic form of cognitive decline)
• •Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness \> 24 hours
• •History of alcohol or drug dependency within the last 2 years
• •Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser)
• •Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser)
• •Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months
• •Carotid stents or severe stenosis
• •Known allergy to fish or any other component in the intervention supplements
• •Existing medical conditions likely to affect the study measures (as judged by clinical adviser)
• •Uncontrolled hypertension (Systolic Blood Pressure (SBP) \>140mmHg, Diastolic Blood Pressure (DBP) \>90mmHg)
• •BMI \>40kg/m2